Healthcare
Chemed Corp(CHE)
Live Price
Offline$436.27
+0.06% today
1Y Change
-19.62%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $5.68B
- Revenue Growth
- +4.1%
- EPS Growth
- -8.4%
- Dividend Yield
- 0.5%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Chemed Corp (CHE) is a Healthcare stock with a market cap of $5.68B and listed on NYSE. The stock last traded around $436.27 and down 19.6% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of -8.4%, a dividend yield of 0.5%. What stands out right now is revenue +4.1%, EPS -8.4%, free cash flow -11.5% with operating margin 12.9% and ROIC 19.5%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.5 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CHE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.1% vs +7.6% peer median
Operating Margin
Below sector median
+12.9% vs +19.4% peer median
P/E
Below sector median
22.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +4.1% and EPS is at -8.4%, with operating margin around 12.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +10.0% | +11.0% | +15.3% |
2026 Feb 25, 2026 | -8.6% | -15.0% | -11.9% | -19.8% |
2025 Oct 28, 2025 | -2.2% | +6.1% | +0.0% | +0.4% |
Benchmark Edge
CHE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHE Max Drawdown
-34.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHE and SPY.
Company Overview
Chemed Corp
NYSE
Chemed Corporation operates as a diversified services company through its two primary segments: VITAS Healthcare and Roto-Rooter. VITAS provides hospice and palliative care services to patients across the United States via a comprehensive network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers, focusing on end-of-life care. Roto-Rooter delivers essential plumbing, drain cleaning, excavation, water restoration, and related maintenance services to both residential and commercial customers through a combination of company-owned branches, independent contractors, and franchisees. This dual-segment structure enables Chemed Corporation to serve distinct yet essential needs in the healthcare and home services markets, offering resilience through non-correlated business lines. Founded in 1970 and headquartered in Cincinnati, Ohio, Chemed Corporation maintains a strong presence in these sectors, supporting communities with critical care and repair solutions.
- Leadership
- Mr. Kevin J. McNamara
- Employees
- 15.7k
- Street Address
- 255 East Fifth Street, Suite 2600
- Mailing
- Cincinnati, OH, 45202-4726
- Region
- Cincinnati, OH, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.5
- EV/EBITDA
- 14.3
- Price/Sales
- 2.2
- Price/Book
- 6.9
Growth
- Revenue
- +4.1%
- EPS
- -8.4%
- Free Cash Flow
- -11.5%
Profitability
- Gross Margin
- 30.3%
- Operating Margin
- 12.9%
- Net Margin
- 10.2%
- ROE
- 25.3%
- ROIC
- 19.5%
Balance Sheet
- Debt/Equity
- 0.28
- Current Ratio
- 0.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.